Protocol Ledger

NCT06544551 · Phase III · COMPLETED

Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

Interventional Phase III clinical trial protocol NCT06544551 sponsored by Beijing Kawin Technology Share-Holding Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-28 Enrollment: 336 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06544551
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)336 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06544551
Protocol FieldVerified Registry Value
NCT IdentifierNCT06544551
Consolidated Lead SponsorBeijing Kawin Technology Share-Holding Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment336 participants (ACTUAL)
Registered Start Date2021-12-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI